GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Dividend Payout Ratio

Sino Biopharmaceutical (HKSE:01177) Dividend Payout Ratio : 0.91 (As of Jun. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Dividend Payout Ratio?

Sino Biopharmaceutical's dividend payout ratio for the months ended in Jun. 2023 was 0.91.

The historical rank and industry rank for Sino Biopharmaceutical's Dividend Payout Ratio or its related term are showing as below:

HKSE:01177' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.05   Med: 0.24   Max: 0.7
Current: 0.7


During the past 13 years, the highest Dividend Payout Ratio of Sino Biopharmaceutical was 0.70. The lowest was 0.05. And the median was 0.24.

HKSE:01177's Dividend Payout Ratio is ranked worse than
65.38% of 130 companies
in the Biotechnology industry
Industry Median: 0.415 vs HKSE:01177: 0.70

As of today (2024-04-26), the Dividend Yield % of Sino Biopharmaceutical is 2.92%.

During the past 13 years, the highest Trailing Annual Dividend Yield of Sino Biopharmaceutical was 4.15%. The lowest was 0.37%. And the median was 0.74%.

Sino Biopharmaceutical's Dividends per Share for the months ended in Jun. 2023 was HK$0.06.

During the past 12 months, Sino Biopharmaceutical's average Dividends Per Share Growth Rate was 100.00% per year. During the past 3 years, the average Dividends Per Share Growth Rate was 34.30% per year. During the past 5 years, the average Dividends Per Share Growth Rate was 17.80% per year. During the past 10 years, the average Dividends Per Share Growth Rate was 19.80% per year.

During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Sino Biopharmaceutical was 58.70% per year. The lowest was -20.60% per year. And the median was 13.85% per year.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Sino Biopharmaceutical Dividend Payout Ratio Historical Data

The historical data trend for Sino Biopharmaceutical's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Dividend Payout Ratio Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Dividend Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.25 0.37 0.05 0.61 0.71

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.35 1.11 0.91 0.42

Competitive Comparison of Sino Biopharmaceutical's Dividend Payout Ratio

For the Biotechnology subindustry, Sino Biopharmaceutical's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's Dividend Payout Ratio falls into.



Sino Biopharmaceutical Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

Sino Biopharmaceutical's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2022 )/ EPS without NRI (A: Dec. 2022 )
=0.097/ 0.16
=0.61

Sino Biopharmaceutical's Dividend Payout Ratio for the quarter that ended in Jun. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Jun. 2023 )/ EPS without NRI (Q: Jun. 2023 )
=0.061/ 0.067
=0.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical (HKSE:01177) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Sino Biopharmaceutical Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical (HKSE:01177) Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines